Navigation Links
Optimer Pharmaceuticals to Present at 20th Annual Credit Suisse Healthcare Conference
Date:11/1/2011

SAN DIEGO, Nov. 1, 2011 /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Company will present at the 20th Annual Credit Suisse Healthcare Conference on Thursday, November 10 at 10:00 AM Eastern Time (7:00 AM Pacific Time).

(Logo:  http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

A live audio webcast of the presentation will be accessible on the Investors page of the Company's website at www.optimerpharma.com.  Replays of the presentation will be available at the same location for 30 days following the conference.

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer has developed and commercialized DIFICID™ (fidaxomicin) tablets, an FDA-approved antibacterial drug for the treatment of adults 18 years of age or older with Clostridium difficile-associated diarrhea (CDAD). Optimer has filed a marketing authorization application with the European Medicines Agency for fidaxomicin. Optimer's clinical pipeline includes Pruvel™, a product in the fluoroquinolone class of antibiotics that has completed Phase 3 trials as a treatment for infectious diarrhea. Additional information can be found at http://www.optimerpharma.com.

Contacts

Optimer Pharmaceuticals, Inc.
David Walsey, VP of Investor Relations and Corporate Communications
858-909-0736

Canale Communications
Jason I. Spark, Senior Vice President
619-849-6005


'/>"/>
SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2011 Financial Results
2. Optimer Pharmaceuticals to Present at the Canaccord Genuity Annual Growth Conference
3. Optimer Pharmaceuticals and Clinical Investigators to Present Data at Upcoming Medical Meetings
4. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
5. Optimer Pharmaceuticals, Inc. Announces Exercise in Full of Underwriters Option to Purchase Additional Shares and Closing of Public Offering of Common Stock
6. Optimer Pharmaceuticals to Present at the 29th Annual J.P. Morgan Healthcare Conference
7. Optimer Pharmaceuticals to Present at Oppenheimer Healthcare Conference
8. Optimer Pharmaceuticals Announces Presentations at Upcoming IDSA Annual Meeting
9. Optimer Announces Presentation of Additional Data from Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection (CDI) Presented at ICAAC
10. Optimer Pharmaceuticals Phase 3 Clinical Trials show Fidaxomicin is Superior to Vancomycin in Treatment of Recurrent Clostridium difficile Infection (CDI); Data Presented at ICAAC
11. Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... May 23, 2017 , ... Kathy Goin ... of Clinical Operations. She brings years of expertise in establishing and leading clinical ... foundation as a licensed occupational therapist, through a variety of leadership roles in ...
(Date:5/22/2017)... ... 2017 , ... Stratevi, a boutique firm that partners with healthcare companies to ... an office in downtown Boston at 745 Atlantic Ave. , “We are seeing ... evidence on the value they provide, not just to patients, but also payers. Having ...
(Date:5/21/2017)... ... May 20, 2017 , ... CNSDose is a genetically driven, ... process by finding the right antidepressant faster. CNSDose speeds recovery and reduces ... a personalized approach to treatment. , A peer-reviewed and published, 12-week ...
(Date:5/18/2017)... ... May 18, 2017 , ... ... The Tapas Cooking Challenge is a two-hour team-building package designed for groups of ... by Chef Jodi Abel, which include items, such as Blackened Shrimp with Edamame ...
Breaking Biology Technology:
(Date:5/16/2017)... , May 16, 2017  Veratad Technologies, LLC ... of online age and identity verification solutions, announced today ... Identity Conference 2017, May 15 thru May 17, 2017, ... Building and International Trade Center. Identity ... globe and in today,s quickly evolving digital world, defining ...
(Date:4/24/2017)... , April 24, 2017 ... and partner with  Identity Strategy Partners, LLP (IdSP) ... "With or without President Trump,s March 6, 2017 ... Terrorist Entry , refugee vetting can be instilled with ... resettlement. (Right now, all refugee applications are suspended ...
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... its 2016 Annual Report on Form 10-K on Thursday April 13, ... ... the Investor Relations section of the Company,s website at http://www.nxt-id.com ... http://www.sec.gov . 2016 Year Highlights: ...
Breaking Biology News(10 mins):